Cyclopharm (ASX:CYC) Managing Director & CEO, James McBrayer presents an update on its radiopharmaceutical products used in imaging, sales of Technegas and its US FDA application at FNN's Investor Event.
Key points:- Cyclopharm Limited
(ASX:CYC) is a leading diagnostic lung imaging company
- Profitable & Growing MedTech
- USA FDA approval set to increase growth
- First in class technology in the 56 countries
- 4M Technegas patient scans
- Opportunity to broaden Technegas applications beyond pulmonary embolism diagnosis
For more infortmation, watch Managing Director & CEO James McBrayer present.
